Notification

Divine Hira Jewellers IPO is Open!

Apply for the Divine Hira Jewellers IPO through UPI in just minutes.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Orchid Pharma Limited Share Price

₹ 838.7 5.50 (0.66%)

Mar 19 2025 03:30 PM Pharmaceuticals NSE: ORCHPHARMA

Orchid Pharma Limited Share Price Update

As of the latest trading session, Orchid Pharma Limited share price is currently at 838.7, which is up by 5.50 from its previous closing. Today, the stock has fluctuated between 830.15 and 874.85. Over the past year, Orchid Pharma Limited has achieved a return of -19.58 %. In the last month alone, the return has been 1.84 %. Read More...

Orchid Pharma Limited Performance

Day Range

Low830.15 High874.85

838.70

52 Week Range

Low 788.55 High 1997.40

838.70

Orchid Pharma Limited Share Price

926

524372

ORCHPHARMA

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

842.00 Prev. Close

833.20 Volume (Shares)

176039.00

Total traded value

1476.43

Upper Circuit

874.85 Lower Circuit

791.55

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Orchid Pharma Limited Fundamentals

(Standalone)

Market Cap (Cr)	4253.81
PE Ratio (TTM)	37.80
Book Value / Share	250.68
Beta	0.99

ROE	3.15%
EPS (TTM)	22.05
Dividend Yield	0.00%
Net Profit Qtr (Cr)	23.91

Orchid Pharma Limited Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	217.34
Operating Expense	203.37
Net Profit	23.91
Net Profit Margin (%)	11.00
Earnings Per Share (EPS)	4.71
EBITDA	36.31
Effective Tax Rate (%)	0.00

Particulars	SEP 2024 (Values in Cr)
Revenue	222.70
Operating Expense	205.04
Net Profit	25.63
Net Profit Margin (%)	11.50
Earnings Per Share (EPS)	5.05
EBITDA	37.56
Effective Tax Rate (%)	0.00

Particulars	JUN 2024 (Values in Cr)
Revenue	244.41
Operating Expense	223.07
Net Profit	29.10
Net Profit Margin (%)	11.90
Earnings Per Share (EPS)	5.74
EBITDA	41.01
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Revenue	217.10
Operating Expense	200.03
Net Profit	33.19
Net Profit Margin (%)	15.28
Earnings Per Share (EPS)	6.86
EBITDA	41.81
Effective Tax Rate (%)	-10.78

Particulars	DEC 2023 (Values in Cr)
Revenue	220.59
Operating Expense	197.48
Net Profit	30.55
Net Profit Margin (%)	13.84
Earnings Per Share (EPS)	6.42
EBITDA	43.36
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Revenue	819.37
Operating Expense	758.24
Net Profit	94.75
Net Profit Margin (%)	11.56
Earnings Per Share (EPS)	19.59
EBITDA	141.07
Effective Tax Rate (%)	-3.52

Particulars	MAR 2023 (Values in Cr)
Revenue	665.90
Operating Expense	669.30
Net Profit	54.19
Net Profit Margin (%)	8.13
Earnings Per Share (EPS)	13.28
EBITDA	142.26
Effective Tax Rate (%)	0.00

Particulars	MAR 2022 (Values in Cr)
Revenue	556.97
Operating Expense	618.75
Net Profit	-4.81
Net Profit Margin (%)	-0.86
Earnings Per Share (EPS)	-1.18
EBITDA	66.25
Effective Tax Rate (%)	0.00

Particulars	MAR 2021 (Values in Cr)
Revenue	450.70
Operating Expense	553.03
Net Profit	-117.15
Net Profit Margin (%)	-25.99
Earnings Per Share (EPS)	-28.70
EBITDA	64.37
Effective Tax Rate (%)	0.00

Particulars	MAR 2020 (Values in Cr)
Revenue	481.21
Operating Expense	593.94
Net Profit	-149.84
Net Profit Margin (%)	-31.13
Earnings Per Share (EPS)	-16.87
EBITDA	33.61
Effective Tax Rate (%)	0.00

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	217.06
ROE %	3.02
ROCE %	3.20
Total Debt to Total Equity	0.25
EBITDA Margin	17.32

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	151.92
ROE %	0.29
ROCE %	1.47
Total Debt to Total Equity	0.45
EBITDA Margin	15.46

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	141.81
ROE %	0.06
ROCE %	-1.10
Total Debt to Total Equity	0.55
EBITDA Margin	11.27

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	143.16
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.72
EBITDA Margin	9.91

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	187.67
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	61.28
EBITDA Margin	-1.43

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	226.69
ROE %	3.15
ROCE %	3.33
Total Debt to Total Equity	0.24
EBITDA Margin	17.26

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	162.53
ROE %	0.81
ROCE %	2.34
Total Debt to Total Equity	0.43
EBITDA Margin	15.46

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	149.30
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.53
EBITDA Margin	12.06

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	150.13
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	0.69
EBITDA Margin	14.26

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	178.67
ROE %	0.00
ROCE %	0.00
Total Debt to Total Equity	88.62
EBITDA Margin	7.39

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	266.56
Total Assets	1553.87
Total Liabilities	1553.87
Total Equity	1169.46
Share Outstanding	50719105
Price to Book Ratio	4.61
Return on Assets (%)	5.93
Return on Capital (%)	7.07

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	30.62
Total Assets	1225.20
Total Liabilities	1225.20
Total Equity	688.64
Share Outstanding	40816400
Price to Book Ratio	2.37
Return on Assets (%)	3.78
Return on Capital (%)	4.54

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	8.06
Total Assets	1110.56
Total Liabilities	1110.56
Total Equity	647.37
Share Outstanding	40816400
Price to Book Ratio	1.90
Return on Assets (%)	-0.17
Return on Capital (%)	-0.21

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	19.91
Total Assets	1237.25
Total Liabilities	1237.25
Total Equity	652.90
Share Outstanding	40816400
Price to Book Ratio	16.42
Return on Assets (%)	-9.41
Return on Capital (%)	-10.76

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	174.04
Total Assets	1459.90
Total Liabilities	1459.90
Total Equity	765.98
Share Outstanding	40816400
Price to Book Ratio	0.00
Return on Assets (%)	-8.97
Return on Capital (%)	-10.32

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	257.22
Total Assets	1552.20
Total Liabilities	1552.20
Total Equity	1218.31
Share Outstanding	50719105
Price to Book Ratio	4.61
Return on Assets (%)	6.10
Return on Capital (%)	7.01

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	22.33
Total Assets	1223.25
Total Liabilities	1223.25
Total Equity	731.96
Share Outstanding	40816400
Price to Book Ratio	2.37
Return on Assets (%)	4.42
Return on Capital (%)	5.1

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	4.20
Total Assets	1094.18
Total Liabilities	1094.18
Total Equity	677.95
Share Outstanding	40816400
Price to Book Ratio	1.90
Return on Assets (%)	-0.43
Return on Capital (%)	-0.51

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	18.96
Total Assets	1224.46
Total Liabilities	1224.46
Total Equity	681.33
Share Outstanding	40816400
Price to Book Ratio	16.42
Return on Assets (%)	-9.56
Return on Capital (%)	-10.33

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	172.31
Total Assets	1449.99
Total Liabilities	1449.99
Total Equity	797.82
Share Outstanding	40816400
Price to Book Ratio	0.00
Return on Assets (%)	-10.33
Return on Capital (%)	-11.51

Particulars	MAR 2024 (Values in Cr)
Net Income	89.04
Cash from Operations	125.36
Cash from Investing	-312.02
Cash from Financing	167.04
Net change in Cash	-18.99
Free Cash Flow	190.17

Particulars	MAR 2023 (Values in Cr)
Net Income	46.31
Cash from Operations	18.63
Cash from Investing	-31.21
Cash from Financing	31.16
Net change in Cash	18.29
Free Cash Flow	103.54

Particulars	MAR 2022 (Values in Cr)
Net Income	-1.95
Cash from Operations	94.38
Cash from Investing	112.93
Cash from Financing	-216.79
Net change in Cash	-11.38
Free Cash Flow	108.78

Particulars	MAR 2021 (Values in Cr)
Net Income	-116.53
Cash from Operations	18.66
Cash from Investing	67.20
Cash from Financing	-164.98
Net change in Cash	-74.19
Free Cash Flow	19.26

Particulars	MAR 2020 (Values in Cr)
Net Income	-131.07
Cash from Operations	70.38
Cash from Investing	167.11
Cash from Financing	-250.33
Net change in Cash	-2.41
Free Cash Flow	74.62

Particulars	MAR 2024 (Values in Cr)
Net Income	91.52
Cash from Operations	129.99
Cash from Investing	-315.80
Cash from Financing	167.06
Net change in Cash	-18.01
Free Cash Flow	185.14

Particulars	MAR 2023 (Values in Cr)
Net Income	54.18
Cash from Operations	13.68
Cash from Investing	-26.69
Cash from Financing	31.16
Net change in Cash	17.85
Free Cash Flow	98.24

Particulars	MAR 2022 (Values in Cr)
Net Income	-4.80
Cash from Operations	91.47
Cash from Investing	112.93
Cash from Financing	-216.79
Net change in Cash	-14.30
Free Cash Flow	105.87

Particulars	MAR 2021 (Values in Cr)
Net Income	-117.15
Cash from Operations	19.44
Cash from Investing	67.20
Cash from Financing	-164.98
Net change in Cash	-73.42
Free Cash Flow	20.04

Particulars	MAR 2020 (Values in Cr)
Net Income	-149.83
Cash from Operations	69.99
Cash from Investing	167.11
Cash from Financing	-250.33
Net change in Cash	-2.79
Free Cash Flow	74.23

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	35.26	18.96	1.92	270.21	34.11 / 77.70
BLISS GVS PHARMA LTD	117.60	15.41	1.22	1239.15	92.25 / 184.95
CIPLA LTD	1508.70	24.42	4.29	121844.87	1317.60 / 1702.00
FERMENTA BIOTECH LIMITED	245.70	20.36	2.49	723.12	145.00 / 449.00

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	35.26	21.24	5.99	270.21	34.11 / 77.70
AMRUTAJAN HEALTH LTD	603.65	35.38	5.86	1745.19	548.05 / 861.40
ASTRAZENECA PHARMA IND LT	7928.65	118.25	29.17	19821.63	4050.15 / 8139.85
BLISS GVS PHARMA LTD	117.60	15.27	1.20	1239.15	92.25 / 184.95

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 836.80
26 Days 996.50
10 Days 868.90
50 Days 1161.70
12 Days 882.40
100 Days 1297.70
20 Days 945.80
200 Days 1287.90

823.88
PIVOT

First Resistance	855.72
Second Resistance	878.23
Third Resistance	910.07

First Support	801.37
Second Support	769.53
Third Support	747.02

RSI	32.87
MACD	-114.16
Commodity Channel Index (CCI)	-95.37

ADX	54.43
Williams % R	-83.73

Orchid Pharma Limited Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

8.64 Promoter Holdings

69.83 FII

2.52 DII

18.99 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Dhanuka Laboratories Limited	Shareholding of Promoter and Promoter Group	3.5419957E7	69.84
Quant Mutual Fund - Quant Small Cap Fund	Public Shareholding	3465947.0	6.83
Invesco India Esg Integration Strategy Fund And 6 Others Under Same Pan	Public Shareholding	2356670.0	4.65
Nippon Life India Trustee Ltd-a/c Nippon India Pharma Fund	Public Shareholding	623032.0	1.23
Jm Financial Mutual Fund - Jm Flexicap Fund And 6 Others Under Same Pan	Public Shareholding	594674.0	1.17
Kotak Mahindra Trustee Co Ltd A/c Kotak Mnc Fund And 3 Others Under Same Pan	Public Shareholding	562991.0	1.11

Orchid Pharma Limited

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2012-09-13	3.0	Final	2012-09-15	Equity shares	2011-07-19	3.0	Final	2011-07-21	Equity shares	2010-07-12	10.0	Final	2010-07-14	Equity shares	2009-09-17	1.0	Final	2009-09-19	Equity shares	2008-09-18	3.0	Final	2008-09-20	Equity shares	2007-07-12	3.0	Final	2007-07-15	Equity shares	2006-05-30	0.0	Final	2006-06-01	Equity shares	2005-07-13	0.0	Interim	2005-07-15	Equity shares

Learn More About Stocks

India proposes 12% safeguard duty on flat steel imports for 200 days

India’s DGTR has proposed a 12% safeguard duty on flat steel imports for 200 days, affecting major steel stocks. JSW Steel share price and Tata Steel share price will be under watch as Nifty Metal Index gains 10% in March 2025.

19 Mar, 2025 | 2 Min. read

Premier Explosives Secures Rs 189 Million Defence Export Order

Premier Explosives secures a Rs 189 million export order for defence explosives, boosting its global presence. Premier Explosives share price likely to be in focus.

19 Mar, 2025 | 2 Min. read

Delhi’s Power Demand to Cross Record 9,000 MW This Summer

Delhi’s power demand is set to exceed 9,000 MW for the first time. Renewable energy sources will support supply. Solar Energy Corporation of India share price in focus.

19 Mar, 2025 | 2 Min. read

G R Infraprojects Secures NHAI Project Worth Rs 42.63 Billion

G R Infraprojects receives a letter of award from NHAI for a project worth Rs 42.63 billion. G R Infraprojects share price likely to remain in focus.

19 Mar, 2025 | 2 Min. read

Moody’s Affirms IndusInd Bank Ratings, Places BCA on Review for Downgrade

Moody’s has affirmed IndusInd Bank’s Ba1 rating with a stable outlook but placed its Baseline Credit Assessment (BCA) on review for downgrade due to risk concerns.

18 Mar, 2025 | 3 Min. read

Manappuram Finance Board to Consider Fundraising Proposals on March 20

Manappuram Finance’s board to meet on March 20 to discuss fundraising through equity shares, warrants, or debt securities. Shares remain in focus amid stake sale reports.

18 Mar, 2025 | 3 Min. read

Tata Motors Incorporates Digital.AI Labs to Expand in IT Sector

Tata Motors has launched Tata Motors Digital.AI Labs Limited, a wholly owned subsidiary focused on IT and digital solutions. Tata Motors share price remains in focus.

18 Mar, 2025 | 3 Min. read

IRCON Wins Rs.285 Crore Order in Meghalaya Secretariat Project

IRCON International secures a Rs.285 crore share in a Rs.1,096.17 crore EPC contract for a new Secretariat Complex in Meghalaya. Project completion is set for 36 months.

18 Mar, 2025 | 3 Min. read

Zydus Life Gets Final USFDA Approval for Eluxadoline Tablets

Zydus Lifesciences Ltd. receives final USFDA approval for Eluxadoline Tablets, 75 mg and 100 mg, securing 180-day shared exclusivity in the US market.

17 Mar, 2025 | 2 Min. read

Galaxy Surfactants Declares ₹18 Per Share Interim Dividend for FY25

Galaxy Surfactants announces an interim dividend of ₹18 per equity share for FY25. The record date is March 20, 2025, with payment to be made within 30 days.

17 Mar, 2025 | 2 Min. read

About Orchid Pharma Limited

Companies Owned by Orchid Pharma Limited

We have something for everyone

Explore More Investment Options

Start Investing

Stocks

Secure and enhance your financial future today

Invest

IPOs

Your gateway to future financial opportunities

Invest

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x

Invest

US Stocks

Discover opportunities to invest in elite FAANG stocks

Invest

Frequently Asked Questions

What is the Share Price of Orchid Pharma Ltd?

Answer Field: The share price of Orchid Pharma Ltd for NSE is ₹ 838.7 and for BSE is ₹ 838.

What is the Market Cap of Orchid Pharma Ltd?

Answer Field: The market cap of Orchid Pharma Ltd for NSE is ₹ 42,53.81 Cr. and for BSE is ₹ 42,50.26 Cr. as of now.

What is the 52 Week High and Low of Orchid Pharma Ltd?

Answer Field: The 52 Week High and Low of Orchid Pharma Ltd for NSE is ₹ 1997.40 and ₹ 788.55 and for BSE is ₹ 1998.00 and ₹ 794.55.

How to Buy Orchid Pharma Ltd share?

Answer Field: You can trade in Orchid Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Orchid Pharma Ltd?

Answer Field: The 1 year returns on the stock has been -19.58%.

What is the Current Share Price of Orchid Pharma Ltd?

Answer Field: Orchid Pharma Ltd share price is for NSE ₹ 838.7 & for BSE ₹ 838 as on Mar 19 2025 03:30 PM.

What is the Market Cap of Orchid Pharma Ltd Share?

Answer Field: The market cap of Orchid Pharma Ltd for NSE ₹ 42,53.81 & for BSE ₹ 42,50.26 as on Mar 19 2025 03:30 PM.

What is the P/E Ratio of Orchid Pharma Ltd Share?

Answer Field: As on Mar 19 2025 03:30 PM the price-to-earnings (PE) ratio for Orchid Pharma Ltd share is 37.80.

What is the PB ratio of Orchid Pharma Ltd Share?

Answer Field: As on Mar 19 2025 03:30 PM, the price-to-book (PB) ratio for Orchid Pharma Ltd share is 250.68.

How to Buy Orchid Pharma Ltd Share?

Answer Field: You can trade in Orchid Pharma Ltd shares with Bajaj Broking by opening a demat accountopens in a new tab.

How to Buy Orchid Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Orchid Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Orchid Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Scan to download

Download from App Store

Download from Play Store

9 lakh+ Users

4.3+ App Rating

4 Languages

₹4300+ Cr MTF Book

Open Demat Account

Divine Hira Jewellers IPO is Open!

Open a Free Demat Account

Trade Now, Pay Later with up to 4x

Track Market Movers Instantly

Orchid Pharma Limited Share Price

Orchid Pharma Limited Share Price Update

Orchid Pharma Limited Performance

Day Range

52 Week Range

Orchid Pharma Limited Share Price

Open Price

842.00

Prev. Close

833.20

Volume (Shares)

176039.00

Total traded value

1476.43

Upper Circuit

874.85

Lower Circuit

791.55

Orchid Pharma Limited Fundamentals

Orchid Pharma Limited Financials

Revenue

Net income

Technicals

Over 1 Month

1.84

Over 3 Months

-53.13

Over 6 Months

-40.61

Over 1 Year

-19.58

Over 3 Years

42.90

Over 5 Years

115.32

Orchid Pharma Limited Future

Future: Price

Discount/Premium

Active Calls

Active Puts

Orchid Pharma Limited Shareholding Pattern

Stock Holding

View Live Stock Screeners

Holding

Public

8.64

Promoter Holdings

69.83

FII

2.52

DII

18.99

Promoter Shares(Pledge Percentage)

0.0

Holding %

Pledges % of promoter shares %

MF Holding %

FII Holding %

Orchid Pharma Limited

Learn More About Stocks

India proposes 12% safeguard duty on flat steel imports for 200 days

Premier Explosives Secures Rs 189 Million Defence Export Order

Delhi’s Power Demand to Cross Record 9,000 MW This Summer

G R Infraprojects Secures NHAI Project Worth Rs 42.63 Billion

About Orchid Pharma Limited

Companies Owned by Orchid Pharma Limited

Explore More Investment Options

Stocks

IPOs

MTF

US Stocks

Frequently Asked Questions

What is the Share Price of Orchid Pharma Ltd?

What is the Market Cap of Orchid Pharma Ltd?

What is the 52 Week High and Low of Orchid Pharma Ltd?

How to Buy Orchid Pharma Ltd share?